Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?
María SolsonaRubén BerruecoElena SebastiánÁurea CerveraAna SastreItziar AstigarragaBienvenida ArgilésMaría Ángeles DasíJosé Luís DapenaEmilio MonteagudoPublished in: British journal of clinical pharmacology (2022)
It is not clear if platelet responses are sustained after thrombopoietin receptor agonist (ar-TPO) withdrawal in paediatric patients. A multicentre retrospective observational study was performed in children with chronic immune thrombopenia (cITP) to describe ar-TPO tapering and withdrawal in patients who had achieved a sustained complete response to ar-TPOs. Ten patients (eltrombopag n = 6, romiplostim n = 4) were included. Treatment withdrawal was performed after a mean tapering time of 7.6 months. Two patients relapsed (median follow-up time of 24 months). Slow tapering and withdrawal of ar-TPOs can be safely performed in cITP paediatric patients after achieving a sustained complete response.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- intensive care unit
- emergency department
- prognostic factors
- peritoneal dialysis
- clinical trial
- patient reported outcomes
- acute lymphoblastic leukemia
- cross sectional
- diffuse large b cell lymphoma
- patient reported
- hodgkin lymphoma
- smoking cessation
- multiple myeloma
- combination therapy